Black Diamond Therapeutics, Inc.
General ticker "BDTX" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $145.9M (TTM average)
Black Diamond Therapeutics, Inc. follows the US Stock Market performance with the rate: 56.2%.
Estimated limits based on current volatility of 3.3%: low 2.61$, high 2.78$
Factors to consider:
- Total employees count: 24 (-55.6%) as of 2024
- Top business risk factors: Labor/talent shortage/retention, Cybersecurity threats, Geopolitical risks, Limited resources, Environmental regulations
- Price in estimated range
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [1.37$, 3.83$]
- 2025-12-31 to 2026-12-31 estimated range: [1.18$, 3.25$]
Financial Metrics affecting the BDTX estimates:
- Positive: with PPE of -1.7 at the end of fiscal year the price was low
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -51.18 <= 0.04
- Positive: Shareholder equity ratio, % of 67.91 > 64.17
- Positive: Interest expense per share per price, % of 0 <= 0.01
- Negative: negative Net income
- Positive: Investing cash flow per share per price, % of 13.94 > -0.62
- Negative: negative Industry operating cash flow (median)
Short-term BDTX quotes
Long-term BDTX plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $92.83MM | $86.46MM | $78.78MM |
| Operating Income | $-92.83MM | $-86.46MM | $-78.78MM |
| Non-Operating Income | $1.66MM | $4.02MM | $9.11MM |
| R&D Expense | $64.44MM | $59.35MM | $51.31MM |
| Income(Loss) | $-91.17MM | $-82.44MM | $-69.68MM |
| Profit(Loss)* | $-91.17MM | $-82.44MM | $-69.68MM |
| Stockholders Equity | $115.69MM | $116.74MM | $83.28MM |
| Assets | $156.25MM | $158.57MM | $122.64MM |
| Operating Cash Flow | $-85.08MM | $-66.72MM | $-62.30MM |
| Capital expenditure | $0.19MM | $0.03MM | $0.00MM |
| Investing Cash Flow | $53.37MM | $16.35MM | $16.97MM |
| Financing Cash Flow | $0.18MM | $71.93MM | $25.55MM |
| Earnings Per Share** | $-2.52 | $-1.88 | $-1.27 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.